Behavioral stress accelerates prostate cancer development in mice.

Area of Science:

• Oncology
• Neuroscience
• Molecular Biology

Background:

• Prostate cancer patients often experience elevated stress and anxiety.
• Beta-blocker use is associated with a lower incidence of prostate cancer, but mechanisms are unclear.
• Stress-induced signaling pathways in prostate cancer progression are not well understood.

Purpose of the Study:

• To investigate the role of stress and adrenaline in prostate cancer development and progression.
• To elucidate the molecular mechanisms linking stress to prostate carcinogenesis.
• To identify potential therapeutic targets for mitigating stress-related prostate cancer outcomes.

Main Methods:

• Utilized mouse models of prostate cancer, including PTEN-deficient xenografts and Hi-Myc mice.
• Administered behavioral stress and pharmacological agents (ICI118,551, PI3K inhibitor, bicalutamide).
• Assessed tumor apoptosis, involution, and development; analyzed signaling pathways involving ADRB2, PKA, and BAD.

Main Results:

• Behavioral stress promoted prostate carcinogenesis in mice in an adrenaline-dependent manner.
• Stress inhibited apoptosis and delayed tumor involution in two distinct prostate cancer models.
• Pharmacological blockade of ADRB2 or inhibition of the PKA/BAD pathway prevented stress-induced tumor progression.

Conclusions:

• Stress promotes prostate cancer growth through an adrenaline/ADRB2/PKA/BAD antiapoptotic signaling pathway.
• Psychosocial factors interact with the tumor microenvironment to influence cancer progression.
• Findings suggest stress reduction or targeted pharmacological interventions could benefit prostate cancer patients.